Compounds > 4-methoxynitracrine
Page last updated: 2024-12-08

4-methoxynitracrine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-methoxynitracrine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID154886
CHEMBL ID312249
MeSH IDM0270809

Synonyms (14)

Synonym
CHEMBL312249
NCI60_018485
nsc652886
ccris 3391
n,n-dimethyl-n'-(4-methoxy-1-nitro-9-acridinyl)-1,3-propanediamine
9-((3-(dimethylamino)propyl)amino)-4-methoxy-1-nitroacridine
4-methoxynitracrine
1,3-propanediamine, n,n-dimethyl-n'-(4-methoxy-1-nitro-9-acridinyl)-
brn 0499404
n'-(4-methoxy-1-nitro-9-acridinyl)-n,n-dimethyl-1,3-propanediamine
n-(4-methoxy-1-nitro-acridin-9-yl)-n',n'-dimethyl-propane-1,3-diamine
9-((3-(dimethylamino)propyl)amino)-1-(hydroxy(oxido)amino)-4-methoxyacridine hydrochloride
25799-70-6
DTXSID40180456
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID9477Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
AID55130Logarithm of association constant for binding to poly[d(A-T)], determined by ethidium displacement1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine.
AID115154Maximum tolerated ip dose for male C3H/HeN mice.1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
AID16679Equilibrium constant measured by the pulse radiolysis at pH 71989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine.
AID228707Compound's one-electron reduction potential (E(1)) has been measured by radiolysis at pK11989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine.
AID9650Inhibitory activity against aerobic growth of AA8 cells.1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
AID233733Air/N2 ratio = C10(air)/C10(nitrogen)1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
AID45253Ratio of cytotoxicity determined in air to that of cytotoxicity determined in N2 was measured under aerobic conditions to hypoxic conditions by the clonogenic assay against Chinese hamster ovary (subline AA8) cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine.
AID29308In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Hypoxia-selective antitumor agents. 6. 4-(Alkylamino)nitroquinolines: a new class of hypoxia-selective cytotoxins.
AID67616Concentration resulting in 10% survival in dissociated EMT6 spheroid cell suspension1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
AID228706Compound''s one-electron reduction potential (E(1)) has been measured by radiolysis at pH 71989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine.
AID231942Ratio for hypoxic AA8/ hypoxic UV-4, expressed as hypersensitivity factor under aerobic conditions1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID232181Ratio of growth inhibition of compound to reduce cell density by 50% of repair deffective mutant UV-4 cells in 96-well cultures under aerobic and hypoxic conditions (air/N2)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID25570Dissociation constant of the compound1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine.
AID230206Inhibitory activity against aerobic growth of UV4cells, Hypersensitivity factor is the ratio of IC50(AA8) to IC50(UV4).1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
AID211493Cytotoxicity was measured under aerobic conditions by the clonogenic assay against Chinese hamster ovary (subline AA8) cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine.
AID215282Inhibitory concentration required to reduce cell density in UV-4 cells to 50% of controls (cells were exposed to compound for 4 days continuously)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID25230Extrapolated fraction of biological activity remaining at time zero of stirred aerobic AA8 suspension cultures1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID25229Extrapolated fraction of biological activity remaining at time zero of hypoxic AA8 suspension cultures1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID232180Ratio of growth inhibition of compound to reduce cell density by 50% of AA8 cells under aerobic and hypoxic conditions (air/N2)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID27864Total compound concentration in AA8 suspension cultures at zero time1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID215281Inhibitory ativity to reduce cell density by 50% of repair deffective mutant UV-4 cells in 96-well cultures under aerobic conditions1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID9664Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Hypoxia-selective antitumor agents. 6. 4-(Alkylamino)nitroquinolines: a new class of hypoxia-selective cytotoxins.
AID9663Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose)1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Hypoxia-selective antitumor agents. 6. 4-(Alkylamino)nitroquinolines: a new class of hypoxia-selective cytotoxins.
AID20518Relative lipophilicity of the compound1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine.
AID27042Half life of extracellular bioactivity assessed by bioassay of culture supernatant against hypoxic UV-4 cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID229914Spheroid resistance factor which is defined as the ratio C10 (intact)/ C10 (dissociated) EMT6 cells1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
AID45746Inhibitory activity to reduce cell density by 50% of AA8 cells under aerobic conditions1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID27040Half life of extracellular bioactivity assessed by bioassay of culture supernatant against aerobic UV-4 cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (40.00)18.7374
1990's3 (60.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.74 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
amsacrine
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.		1.9710acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
chlorambucil
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.		1.9710aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
mitomycin
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.		1.9710mitomycinalkylating agent;
antineoplastic agent
4-nitroquinoline-1-oxide
4-nitroquinoline N-oxide : A quinoline N-oxide carrying a nitro substituent at position 4.		1.9710C-nitro compound;
quinoline N-oxide		carcinogenic agent
ethyl methanesulfonate
Ethyl Methanesulfonate: An antineoplastic agent with alkylating properties. It also acts as a mutagen by damaging DNA and is used experimentally for that effect.. ethyl methanesulfonate : A methanesulfonate ester resulting from the formal condensation of methanesulfonic acid with ethanol.		1.9710methanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
genotoxin;
mutagen;
teratogenic agent
c 137
C 137: RN given refers to parent cpd		1.9710
nitracrine
Nitracrine: Acridine antineoplastic agent used in mammary and ovarian tumors. It inhibits RNA synthesis.		3.0850acridines
misonidazole
Misonidazole: A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic.		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials